Nanoparticle albumin-bound (nab)-paclitaxel for the treatment of pancreas ductal adenocarcinoma

Vignesh Narayanan1
Colin D Weekes1,2
1Division of Medical Oncology, Department of Medicine, 2Developmental Therapeutics Program, University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, CO, USA

Abstract: Pancreatic adenocarcinoma is a leading cause of cancer-related mortality worldwide, and surgical resection offers the only chance of cure. Since the majority of patients have unresectable disease at presentation, the emphasis has been on identifying effective chemotherapy regimens to prolong survival and control tumor burden. Gemcitabine has been the cornerstone of treatment ever since it was discovered to be an active agent in advanced pancreatic cancer nearly two decades ago, but the overall prognosis in patients with metastatic disease remains dismal. A dense fibrotic stroma around the tumor devoid of vasculature and the resultant hypoxic tumor microenvironment are implicated in the chemotherapy-resistant nature of this malignancy. In recent years, a growing body of literature has further elucidated several aspects of pancreatic tumor biology, such as its ability to utilize albumin from the peritumoral tissues to support its metabolic needs. High-pressure homogenization of paclitaxel with nanoparticle albumin results in the formation of soluble 130 nm complexes with albumin acting as the carrier for the otherwise hydrophobic paclitaxel. Once these complexes reach the tumor milieu, they act by depleting the tumor stroma. In addition, paclitaxel is also transported into the tumor cell along with albumin, where it then exerts its antineoplastic activity. Nanoparticle albumin-bound (nab)-paclitaxel also increases gemcitabine levels inside the tumor cells by inhibiting cytidine deaminase, the enzyme that degrades gemcitabine. This review focuses on proposed mechanisms of efficacy of nab-paclitaxel in pancreatic cancer and discusses the preclinical and clinical studies of relevance.

Keywords: pancreatic adenocarcinoma, nab-paclitaxel, gemcitabine, SPARC, tumor stroma

Introduction

The treatment of exocrine pancreatic ductal adenocarcinoma (PDA) poses a tremendous therapeutic challenge to the oncology community. In the USA and other developed countries, pancreatic cancer constitutes less than 3% of new cancers diagnosed each year, yet the mortality associated with it is inexorably high.1–4 Among gastrointestinal malignancies in the USA, the annual incidence of pancreatic cancer is much lower than that of colorectal cancer (46,420 versus 136,830 estimated new cases per year, respectively). However, the mortality ensuing from pancreatic cancer is second only to colorectal cancers (39,590 versus 50,310 estimated deaths per year, respectively), and almost all patients with pancreatic cancer are likely to die from it.4 The incidence of pancreatic cancer is also projected to increase in the years to come, and it is ominously predicted to surpass breast, prostate, and colon cancer to become the second leading cause of cancer-related mortality by the year 2030.5

Several factors contribute to the lethality of pancreatic cancer (Table 1). Due to the nonspecific nature of heralding symptoms and the lack of biomarkers to identify
patients at risk, most patients present with locally advanced or metastatic disease. PDA tumors are characterized by a notoriously intense fibrotic or “desmoplastic” reaction surrounding the tumor cells that contributes to increased extracellular fluid pressure, resulting in collapse of blood vessels in the tumor stroma.6 The resultant hypoxic peritumoral milieu is thus a significant impediment to the effective delivery of chemotherapy to the tumor.7 Based on genomic analyses of pancreatic tumors by next-generation sequencing, PDAs have been found to exhibit a wide array of genetic abnormalities and core signaling abnormalities that enhance tumorigenesis.8 Remarkable variations in genetic abnormalities in individual tumors have also been described and this heterogeneity adds complexity to the utilization of molecularly targeted therapeutics.8 Even though patients with early-stage disease undergo curative intent treatment by surgical resection followed by adjuvant therapy, nearly 80% relapse, and eventually succumb to this recalcitrant malignancy.9–11 Historically, the prognosis of patients with metastatic disease is even more dismal, as less than half of patients will survive beyond one year with therapy.12,13

Since most PDAs are unresectable at presentation, the onus has been on chemotherapy regimens to control tumor burden, reduce symptoms, and prolong overall survival (OS). However, in the past two decades, impactful therapeutic regimens have been few and far between. In the late 1990s, gemcitabine emerged as an effective treatment option based on the results of a sentinel study.14 When compared with 5-fluorouracil, the clinical benefit response with gemcitabine was higher (5% versus 24%, \( P=0.002 \)), and it also prolonged OS by 1.2 months (4.4% versus 5.6 months, \( P=0.002 \)).

Since then, several combination chemotherapy regimens using a gemcitabine backbone have been studied, but despite improved overall response rates (ORR), none have resulted in meaningful prolongation of OS in advanced disease.15–19 Erlotinib, a tyrosine kinase inhibitor directed against the human epidermal growth factor receptor, garnered great interest in the realm of molecularly targeted antineoplastic therapy for metastatic PDA.20 In a pivotal trial, the addition of erlotinib to gemcitabine resulted in a survival advantage compared with gemcitabine alone (hazard ratio [HR] for death 0.82; 95% confidence interval [CI] 0.69–0.99, \( P=0.04 \)), but the OS was prolonged by a mere 2 weeks, a result that is uniformly perceived as not clinically meaningful.20 More recently, the results from a study group in France confirmed the superiority of the combination regimen of 5-fluorouracil, oxaliplatin, and irinotecan (FOLFIRINOX) over gemcitabine monotherapy in yet another landmark trial.21 When compared with single-agent gemcitabine, this combination regimen confers a median survival advantage of 4.3 months (HR for death 0.57; 95% CI 0.45–0.73, \( P<0.001 \)) and a progression-free survival (PFS) improvement of 3.1 months (HR for disease progression 0.47; 95% CI 0.37–0.59, \( P<0.001 \)).21 However, patients with metastatic disease and good performance status were rigorously selected and patients with carcinoma of the head of the pancreas constituted less than 40% of the study population. Moreover, a significantly higher proportion of patients experienced grade 3 or 4 neutropenia, febrile neutropenia, thrombocytopenia, fatigue, sensory neuropathy, and diarrhea. Thus, the toxicity profile of this regimen significantly limits its applicability to a large proportion of PDA patients, namely the elderly and those with poor performance status.

Currently, the therapeutic landscape of pancreatic adenocarcinoma is in an exciting phase owing to research that has better defined the molecular mechanisms of PDA oncogenesis and maintenance, although implementing this information in the clinical setting has not been feasible thus far. However, recent studies have shown that altering the PDA stroma by specifically targeting the extracellular matrix holds promise.22–24 This review focuses on the novel mechanistic effects of nanoparticle albumin-bound (nab)-paclitaxel on the tumor stroma as well as its preclinical pharmacology and clinical utility in the treatment of patients with PDA.

**Solvent-based paclitaxel**

Paclitaxel was first isolated from the bark of *Taxus brevifolia*, also known as the Pacific yew tree, found in North America.25 The potent antineoplastic activity of paclitaxel is attributed to its ability to disrupt microtubule assembly, resulting in death of cancer cells by mitotic catastrophe.26 During the initial stages of drug development, the insolubility of paclitaxel in aqueous medium was a major hurdle in ensuring effective drug delivery. The use of polyethoxylated castor
oil (Cremophor EL®, BASF Corporation, Ludwigshafen, Germany) as a solvent mitigated this issue by rendering paclitaxel more soluble, but this strategy is associated with several limitations. Cremophor is implicated in the notorious propensity of paclitaxel to cause infusional hypersensitivity reactions, which tend to be severe in up to 10% of patients who receive it, therefore necessitating premedication with steroids and antihistamines.\(^{27,28}\) Hepatotoxicity is a feared complication attributed to the corrosive effects of Cremophor on plasticizers in standard intravenous infusion tubes, and hence requires special polyvinyl chloride-free tubing with an in-line filter.\(^{29}\) Importantly, Cremophor causes entrapment of paclitaxel in large micelles, which decreases bioavailability, resulting in impaired efficacy.\(^{30}\) In addition, sequestration of paclitaxel in micelles leads to nonlinear pharmacokinetics and decreased clearance of the drug, which increases systemic exposure and toxicity.\(^{31}\) Paclitaxel-induced peripheral neuropathy may be severe, irreversible, and dose-limiting, and Cremophor is purported to play a role because it can cause axonal degeneration and demyelination.\(^{32}\)

Although solvent-based paclitaxel is an active agent in combating many different malignancies, its efficacy in patients with PDA has been disappointing. In clinical studies, single-agent paclitaxel in unresectable PDA induces an ORR of less than 10%, without any improvement in PFS or OS.\(^{33,34}\) Similarly poor results have also been seen with paclitaxel in gemcitabine-refractory disease.\(^{35,36}\) The use of docetaxel likewise demonstrated limited clinical efficacy in PDA patients.\(^{37–39}\)

### Nanotechnology in creation of nab-paclitaxel

Particles between the sizes of 1 and 1,000 nanometers (nm) are called nanoparticles. A high surface to volume ratio augments their interaction with other molecules, and allows for tremendous versatility in enhancing drug delivery across difficult biological barriers, such as the blood–brain and blood–tumor barriers.\(^{40}\) Another prime advantage of nanotechnology is in rendering hydrophobic molecules such as paclitaxel soluble in aqueous media by enveloping it in albumin nanoparticles.\(^{40}\) When human serum albumin at a concentration of 3%–4%, akin to its natural concentration in blood, is mixed with paclitaxel in an aqueous solvent and passed through a jet under high pressure, it results in the conjugation of albumin with paclitaxel and leads to the formation of spherical nanoparticles with a mean diameter of 130 nm.\(^{41}\) Paclitaxel forms the center of the nanoparticle that is covered by a thin outer layer of albumin.\(^{40}\) The inherent negative surface charge of albumin and its solubility in aqueous media prevents agglomeration of the nanoparticles and confers stability in suspension.\(^{40}\) Due to the noncovalent binding of paclitaxel with albumin through hydrophobic interaction, the complexes dissociate rapidly after intravenous infusion to aid rapid tissue distribution.\(^{40}\)

Nab-paclitaxel (Abraxane®, Celgene Inc., Odenton, MD, USA) has several advantages compared with Cremophor-based paclitaxel (Table 2), and first received US Food and Drug Administration approval based on its efficacy in the treatment of refractory metastatic breast cancer in 2005.\(^{42}\) It is also currently approved for the treatment of metastatic non-small-cell lung cancer and recently received approval for the treatment of metastatic PDA in September 2013.\(^{42}\)

### Preclinical evidence

Several preclinical studies have shed light on the biological basis for the efficacy of nab-paclitaxel in pancreatic cancer (Table 3).

### Interactions of nab-paclitaxel with albondin (gp60) and caveolin

Utilization of certain physiological attributes of albumin, such as its ubiquity in plasma and activity as a transport protein, ensures an effective mechanism for delivery of paclitaxel. The strong binding affinity between human serum albumin and paclitaxel is an added advantage that provides enhanced stability to the nab-paclitaxel formulation.\(^{43}\) Each 50 mL vial contains 100 mg of nab-paclitaxel and 900 mg of human albumin, and upon reconstitution with 20 mL of 0.9% sodium chloride, each mL of suspension contains 5 mg of nab-paclitaxel.\(^{44}\) After intravenous infusion, the nanoparticles dissociate into individual soluble albumin-paclitaxel complexes, which then bind to the albumin receptor called albondin or glycoprotein 60 (gp60).\(^{45}\) Transmembrane scaffolding proteins belonging to the caveolin family then mediate transcytosis of nab-paclitaxel across the endothelial cell into the peritumor interstitium.\(^{46,47}\) Due to the specific

<table>
<thead>
<tr>
<th><strong>Table 2. Differences between solvent-based paclitaxel and nab-paclitaxel</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Solvent</strong></td>
</tr>
<tr>
<td><strong>Pharmacokinetics</strong></td>
</tr>
<tr>
<td><strong>Hypersensitivity</strong></td>
</tr>
<tr>
<td><strong>Premedication</strong></td>
</tr>
<tr>
<td><strong>Special infusion tubing</strong></td>
</tr>
<tr>
<td><strong>Infusion time</strong></td>
</tr>
</tbody>
</table>

**Abbreviation:** SB, solvent-based.
interaction between albumin, gp60 and activation of caveolin, a higher concentration of drug is delivered to the tumor when compared with Cremophor-paclitaxel. In preclinical studies using xenograft models, a ten-fold increase in endothelial cell binding and a four-fold increase in transcytosis were observed with nab-paclitaxel when compared with Cremophor-paclitaxel.\textsuperscript{48} Further, in this study, Cremophor inhibited caveolar transport, thus explaining its inferiority in achieving drug delivery into tumor cells.\textsuperscript{48} Since PDA cells depend on albumin for their metabolic needs, paclitaxel is taken up into the tumor cells by virtue of being bound to albumin nanoparticles and subsequently exerts its antineoplastic activity.\textsuperscript{49,50}

**Role of SPARC**

Secreted protein acidic and rich in cysteine (SPARC) is a matrix glycoprotein with varied functions, such as angiogenesis, cell proliferation, cell differentiation, and cell migration, as well as tissue remodeling and wound repair.\textsuperscript{51} It is expressed in normal tissues where it serves as a marker of activated fibroblasts.\textsuperscript{52} It is also overexpressed in multiple malignancies, although its exact role in tumorogenesis is not clearly understood.\textsuperscript{53} Despite loss of expression of SPARC in pancreatic cancer cells, the fibroblasts around the tumor continue to express SPARC, where it is proposed to aid metastasis.\textsuperscript{51} Gene expression analyses have also established SPARC as a crucial driver of the invasiveness of pancreatic cancer.\textsuperscript{54}

Infante et al investigated the prognostic significance of SPARC expression in PDA cells and in the tumor stroma in a cohort of 299 patients who underwent pancreaticoduodenectomy at Johns Hopkins Hospital over a period of 5.5 years between 1998 and 2003.\textsuperscript{55} Patients whose pancreatic cancer stromal fibroblasts (but not PDA cells) expressed SPARC fared significantly worse compared with patients whose tumor stroma did not express SPARC (median survival 15 months versus 30 months, respectively; log rank \(P<0.001\)). This prognostic information laid the platform for recent studies that have investigated the relationship between nab-paclitaxel and overexpression of SPARC in PDA. As part of the Phase I/II study of gemcitabine plus nab-paclitaxel in advanced PDA, Von Hoff et al evaluated the SPARC status of 36 patients and classified them into high-SPARC and low-SPARC groups.\textsuperscript{56} The OS of patients with high SPARC expression was significantly better than the low-SPARC group (median OS 18 months versus 8 months, \(P=0.043\)), suggesting stromal SPARC as a potential target of nab-paclitaxel. After entry of nab-paclitaxel into the peritumoral interstitium from the vascular endothelium through the previously discussed albumin-gp60-caveolin pathway, SPARC is proposed to facilitate the transfer of drug into the tumor cells.\textsuperscript{55} However, the role of SPARC in facilitating delivery of nab-paclitaxel is debatable based on the results of two recent reports. First, Neesse et al demonstrated in a genetically engineered mouse model devoid of SPARC that the effect of murine nab-paclitaxel was dose-dependent and thus independent of SPARC expression.\textsuperscript{56} Second, analyses of SPARC expression in the pivotal Phase III MPACT study were recently presented as an oral abstract at the European Society of Medical Oncology.\textsuperscript{57} Contrary to the results of the Phase I/II study, expression of SPARC was not associated with OS, but the final results are yet to be published. Thus, the role of SPARC in delivery of nab-paclitaxel might not be as important as previously thought.

**Depletion of tumor stroma**

The milieu around PDA consists of both matrix proteins such as collagen, hyaluronic acid, and the aforementioned SPARC, as well as a mixture of cancer-associated fibroblasts and endothelial and inflammatory cells.\textsuperscript{5,7} Depletion of this tumor stroma and curtailing the desmoplastic reaction is therefore considered a crucial strategy in stopping the growth of PDA.\textsuperscript{5}

In a small but novel study, Alvarez et al administered nab-paclitaxel and gemcitabine to 16 patients in a neoadjuvant fashion and determined the effects of this combination regimen on the tumor stroma by endoscopic ultrasound elastography and examination of surgically resected tumor specimens.\textsuperscript{58} Not only was there a significant decrease in tumor stiffness on endoscopic ultrasound elastography, but there was also a decrease in cancer-associated fibroblasts and significant disruption of the intense collagen architecture.

---

**Table 3 Proposed mechanisms for efficacy of nab-paclitaxel in pancreatic cancer in preclinical studies**

<table>
<thead>
<tr>
<th>Barrier</th>
<th>Proposed MOA of nab-paclitaxel</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Impaired drug delivery</td>
<td>Transcytosis by gp60, caveolin</td>
<td>Peritumoral drug delivery</td>
</tr>
<tr>
<td></td>
<td>Endocytosis by SPARC</td>
<td>Intratumoral drug delivery</td>
</tr>
<tr>
<td>Desmoplastic stroma</td>
<td>Stromal depletion</td>
<td>Impaired tumor defense</td>
</tr>
<tr>
<td>Macropinocytosis of albumin</td>
<td>engulfment of albumin-bound paclaxel</td>
<td>Intratumoral drug delivery</td>
</tr>
<tr>
<td>Gemcitabine resistance</td>
<td>Cytidine deaminase inhibition</td>
<td>Increased intratumoral drug delivery</td>
</tr>
</tbody>
</table>

Abbreviations: MOA, mechanism of action; gp60, glycoprotein 60; SPARC, secreted protein, acidic and rich in cysteine.
among patients treated with this regimen. Similarly, stromal disruption was noted in patient-derived xenograft mouse models treated with nab-paclitaxel and gemcitabine in the study by Von Hoff et al. In their study, genetically engineered mice bearing tumors received nab-paclitaxel, gemcitabine, or a combination of these two agents. Although similar responses were observed in mice treated with nab-paclitaxel, an increase in collagen and cancer-associated fibroblasts was documented in the gemcitabine-only group. Thus, stromal disruption is an exclusive effect of nab-paclitaxel. In addition, the intratumoral concentration of gemcitabine was nearly 3-fold higher in mice treated with nab-paclitaxel plus gemcitabine than in those receiving gemcitabine alone. The exact mechanism of action of nab-paclitaxel in depleting the tumor stroma has not been elucidated, but could be mediated by SPARC.

Oncogenic K-ras and macropinocytosis

Upwards of 95% of PDA tumors possess activating mutations of the Kras oncogene, most commonly at the G12 residue. Kras activating mutations are also early inciting events in pancreatic malignancies, and mutations are found in every stage in the continuum from pancreatic intraepithelial neoplasia to overt adenocarcinoma. Despite intensive efforts, direct pharmacological inhibition of Kras has been unsuccessful. Hence, inhibiting downstream pathways and Kras-mediated mechanisms of tumor survival have been pursued with varying degrees of success. Macropinocytosis is one such mechanism of tumor survival, wherein extracellular fluid proteins are internalized by the formation of large vesicles known as macropinosomes. This process constitutes an important route of nutrient uptake in PDA. Commisso et al demonstrated that Ras-transformed cells induce macropinocytosis in PDA cell lines. Compared with PDA cell lines with wild-type Kras, cell lines with homozygous Kras activating mutations display higher tetramethylrhodamine-dextran (a marker for macropinocytosis). In addition, knockdown of Kras results in macropinocytosis being shut off. Since two-thirds of extracellular fluid consists of plasma proteins and because albumin is the most abundant plasma protein, it is conceivable that by virtue of binding albumin with paclitaxel, macropinocytosis might result in enhanced uptake of paclitaxel, akin to a Trojan-horse phenomenon. However, this hypothesis is yet to be proven in clinical studies.

Potentiation of the effect of gemcitabine

In a genetically engineered mouse model of pancreatic cancer, administration of gemcitabine in combination with nab-paclitaxel prevented the growth of tumors in some mice and even resulted in regression of tumor in others. However, when gemcitabine was administered as a single agent, the tumors more than doubled in size, and although nab-paclitaxel monotherapy had some antitumor activity, none of the tumors regressed. The authors discovered that intratumoral levels of gemcitabine were higher when administered with nab-paclitaxel. This synergy is due to the inhibition of the gemcitabine-metabolizing enzyme, cytidine deaminase, by paclitaxel-induced formation of reactive oxygen species. This eventually results in enhanced stability of gemcitabine as well.

Clinical evidence

Phase I/II

The combination of nab-paclitaxel and gemcitabine in the first-line treatment of metastatic pancreatic cancer was studied in a multicenter, open-label Phase I/II trial. In the Phase I portion, the primary aim was to identify the maximum tolerated dose and dose-limiting toxicities of gemcitabine at a dose of 1,000 mg/m² followed by nab-paclitaxel at a dose of 100, 125, or 150 mg/m², given intravenously on days 1, 8, and 15 every 28 days, using a standard 3 + 3 dose-escalation design. Accrual was continued at the maximum tolerated dose in the Phase II portion of the study to determine the safety and efficacy of the combination in addition to the decline in CA19-9 levels and positron emission tomography scan response with treatment. The role of SPARC as a biomarker was also studied (as discussed previously).

Overall, of the 67 patients recruited, 20, 44, and three patients received nab-paclitaxel at 100, 125, and 150 mg/m², respectively, and the maximum tolerated dose was 1,000 mg/m² of gemcitabine and 125 mg/m² of nab-paclitaxel once weekly for 3 weeks every 28 days. Subsequently, 44 patients were treated at the maximum tolerated dose; median PFS was 7.9 months (95% CI 5.8–11) and median OS was 12.2 months (95% CI 8.9–17.9). The ORR was 46% for all 67 patients and 48% for those treated at the maximum tolerated dose, with a one-year survival rate of 48%. Positron emission tomography scan results revealed a median decrease in metabolic activity of 79%, and patients with a complete metabolic response had a significantly improved OS compared with those who did not (median 20.1 versus 10.3 months, P=0.01). CA19-9 levels decreased rapidly, with a median time to maximum decrease of 89 days and a median maximum change of 91%. Patients with a greater than 50% decline in CA19-9 levels had better median OS (13.6 versus 6.5 months), PFS (8 versus 3.6 months), and ORR (62% versus 33%), compared with patients with a less than 50% decline.
Treatment with this regimen was also well tolerated, with the majority of treatment-related adverse effects being grade 1 or 2 in severity. Sepsis and neutropenia were the major dose-limiting toxicities. At the maximum tolerated dose, the most commonly encountered grade 3 or higher adverse effects were fatigue (27%) and neuropathy (20%). Of the grade 3 or higher treatment-related hematological toxicities, neutropenia (67%), leukopenia (44%), and thrombocytopenia (23%) were the most common. This study was unique because of the multifaceted assessment of tumor response using positron emission tomography scans in addition to conventional methods and analysis of biomarkers. The ORR, PFS, and OS realized with this combination regimen proved to be the highest among any of the reported Phase II trials in patients with PDA, and led to significant optimism to further validate the results in a Phase III trial (discussed in the “Phase III” section).

Zhang et al reported the results of a Phase I/II study among Chinese patients with advanced PDA treated with nab-paclitaxel at 80, 100, or 120 mg/m², in combination with gemcitabine at 1,000 mg/m² on days 1 and 8, repeated every 21 days. Of the 21 patients enrolled in this study, the maximum tolerated dose of nab-paclitaxel was established at 120 mg/m². Elevated alanine aminotransferase and febrile neutropenia were the dose-limiting toxicities, and the safety profile was favorable. The ORR (42%) and OS (12.7 months) were consistent with the results reported in the aforementioned Phase I/II study by Von Hoff et al. The addition of capcitabine to the combination of nab-paclitaxel and gemcitabine was also studied in a Phase I trial by Ko et al. Chemotherapy treatment cycles were 14 days long, with capcitabine given on days 1–7 and both gemcitabine and nab-paclitaxel given on day 4. From the 14 patients in this study, the maximum tolerated dose of pacitaxel was established at 100 mg/m² intravenously, gemcitabine 750 mg/m² intravenously, and capcitabine 750 mg/m² orally twice daily. Although the regimen was well tolerated, the ORR (14%), OS (7.5 months), and PFS (4.5 months) were markedly lower compared with other studies. Although the authors explained these marginal results owing to suboptimal dosing of each separate drug component in the regimen at maximum tolerated dose, the small sample size is a limiting factor in drawing conclusions from this trial.

In another Phase I study, patients with metastatic pancreatic cancer were stratified into two cohorts and received nab-paclitaxel at a fixed dose of either 100 mg/m² intravenously weekly for 3 weeks every 28 days or 260 mg/m² every 3 weeks in combination with three escalating doses (100 mg, 200 mg, or 300 mg per day) of the oral vascular endothelial growth factor receptor/RET/epidermal growth factor receptor antagonist, vandetanib. One dose-limiting toxicity at each dose level of vandetanib was observed in the weekly nab-paclitaxel cohort, while no dose-limiting toxicities were seen in the second cohort. Of the 29 patients who were treated, 22 were evaluable, and six (27.5%) had a partial response, ten (45%) had stable disease, and six (27.5%) had progressive disease. The median PFS and OS were 5.3 months (95% CI 3.7–7.3) and 8.2 months (95% CI 6.2–11.5), respectively. The maximum tolerated dose in both cohorts was the maximum planned dose of vandetanib. Treatment was well tolerated in both cohorts.

Phase III

MPACT was a Phase III, open-label international study that enrolled patients with metastatic pancreatic cancer at 151 centers in eleven countries. Eligible patients were randomized to receive nab-paclitaxel (125 mg/m²) followed by gemcitabine (1,000 mg/m²) on days 1, 8, and 15 every 4 weeks or monotherapy with gemcitabine (1,000 mg/m²) weekly for 7 of 8 weeks for the first cycle and then on days 1, 8, and 15 every 4 weeks from the second cycle onwards. Patients were assessed for response every 8 weeks with computed tomography scans or magnetic resonance imaging along with serial measurements of CA19-9. In the intention to treat population, the primary end point of median OS was 8.5 months with nab-paclitaxel plus gemcitabine as compared with 6.7 months with gemcitabine monotherapy (HR for death 0.72; 95% CI 0.62–0.83, P<0.001). The secondary end point of median PFS was 5.5 months in the combination chemotherapy arm versus 3.7 months in the monotherapy arm (HR for disease progression or death 0.69; 95% CI 0.58–0.82, P<0.001). The ORR was also significantly better (23% versus 7%, P<0.001) in favor of nab-paclitaxel and gemcitabine.

Grade 3 or higher neutropenia was more common with the combination of two agents than with gemcitabine alone (38% versus 27%), and necessitated growth factor support more frequently (26% versus 15%). Although grade 3 or higher neutropenia was more common with the doublet (17% versus 1%), it was rapidly reversible when nab-paclitaxel was interrupted, with a median time to resolution of 29 days and was seldom responsible for discontinuation of nab-paclitaxel (8%). Grade 3 or higher fatigue was also more common with the combination (17% versus 7%), as was sepsis (5% versus 2%) and pneumonitis (4% versus 1%), although fatalities amounted to 4% in both groups. Adherence to treatment and dose intensity were high with both agents, and the median cumulative dose...
of gemcitabine administered was higher in the combination treatment arm, reflecting the increased duration of treatment in this group.

The MPACT trial has several positive attributes, such as multinational enrollment, evaluation of OS as a primary endpoint as compared with PFS, and inclusion of patients with poor performance status (8%) and advanced age (10%), all of which greatly increase the applicability of the trial’s results to a wider range of patients with advanced PDA. Minor limitations of the study include a nonclassical dose modification schedule and lack of quality of life measurement. Its favorable toxicity profile and convenience due to a weekly dosing schedule without requirement of home infusion pumps also make this combination regimen more attractive as a palliative treatment option (see Table 4 for comparison of results from the MPACT and FOLFIRINOX trials). The combination of improved response rate and OS makes utilization of this combination therapy attractive for implementation in earlier disease settings, such as neoadjuvant, unresectable locally advanced disease, and as adjuvant therapy (Table 5). The role of this combination as well as FOLFIRINOX in an earlier disease setting is currently under investigation, and the results of these clinical trials are yet to be reported. The toxicity profile of the combination of gemcitabine and nab-paclitaxel also allows this combination to serve as a cytotoxic chemotherapy backbone for the addition of molecular targeted therapies. Many such clinical trials are ongoing or in development.69

Table 4 Comparison of results from the MPACT and FOLFIRINOX trials

<table>
<thead>
<tr>
<th>Study (n)</th>
<th>Median OS months</th>
<th>Median PFS months</th>
<th>ORR</th>
<th>One-year survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gemcitabine* (n=430)</td>
<td>6.7</td>
<td>3.7</td>
<td>7%</td>
<td>22%</td>
</tr>
<tr>
<td>Nab-paclitaxel + gemcitabine (n=431)</td>
<td>8.5</td>
<td>5.5</td>
<td>23%</td>
<td>35%</td>
</tr>
<tr>
<td>FOLFIRINOX (n=342)</td>
<td>12.2</td>
<td>6.4</td>
<td>31.6</td>
<td>48.4%</td>
</tr>
</tbody>
</table>

Notes: *Gemcitabine control cohort from MPACT trial (results comparable with FOLFIRINOX control group).

Abbreviations: FOLFIRINOX, 5-fluorouracil, leucovorin, irinotecan, oxaliplatin; OS, overall survival; PFS, progression-free survival; ORR, overall response rate.

Table 5 Ongoing clinical trials involving nab-paclitaxel in the treatment of non-metastatic PDA, stratified by treatment setting (according to http://www.clinicaltrials.gov, accessed September 2014)

<table>
<thead>
<tr>
<th>Clinical trial identifier</th>
<th>Setting</th>
<th>Medications studied</th>
<th>Phase</th>
<th>Status</th>
<th>Estimated completion date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT01431794</td>
<td>Neoadjuvant; borderline resectable</td>
<td>nab-Pac + Gem + LDE-225</td>
<td>I/II</td>
<td>Recruiting</td>
<td>September 2016</td>
</tr>
<tr>
<td>NCT02210559</td>
<td>Neoadjuvant; locally advanced, unresectable</td>
<td>nab-Pac + Gem ± FG-3019</td>
<td>II</td>
<td>Recruiting</td>
<td>July 2016</td>
</tr>
<tr>
<td>NCT02125136</td>
<td>Neoadjuvant; locally advanced</td>
<td>nab-Pac + Gem versus FOLFIRINOX</td>
<td>II</td>
<td>Not yet recruiting</td>
<td>December 2017</td>
</tr>
<tr>
<td>NCT01470417</td>
<td>Neoadjuvant</td>
<td>nab-Pac + Gem versus nab-Pac + Gem + radiotherapy</td>
<td>II</td>
<td>Ongoing, not recruiting</td>
<td>January 2014</td>
</tr>
<tr>
<td>NCT01726582</td>
<td>Neoadjuvant</td>
<td>nab-Pac + Gem versus other*</td>
<td>II</td>
<td>Recruiting</td>
<td>June 2015</td>
</tr>
<tr>
<td>NCT01298011</td>
<td>Neoadjuvant</td>
<td>nab-Pac + Gem</td>
<td>II</td>
<td>Ongoing, not recruiting</td>
<td>December 2013</td>
</tr>
<tr>
<td>NCT02047513</td>
<td>Neoadjuvant + adjuvant versus adjuvant only; resectable</td>
<td>nab-Pac + Gem</td>
<td>II</td>
<td>Not yet recruiting</td>
<td>March 2019</td>
</tr>
<tr>
<td>NCT01978184</td>
<td>Neoadjuvant, potentially resectable</td>
<td>nab-Pac + Gem ± hydroxychloroquine</td>
<td>II</td>
<td>Recruiting</td>
<td>November 2017</td>
</tr>
<tr>
<td>NCT02243007</td>
<td>Neoadjuvant</td>
<td>nab-Pac + Gem versus FOLFIRINOX</td>
<td>II</td>
<td>Not yet recruiting</td>
<td>July 2018</td>
</tr>
<tr>
<td>NCT01964430</td>
<td>Adjuvant</td>
<td>nab-Pac + Gem versus Gem</td>
<td>III</td>
<td>Recruiting</td>
<td>April 2019</td>
</tr>
<tr>
<td>NCT02020201</td>
<td>Adjuvant</td>
<td>nab-Pac + Gem</td>
<td>II</td>
<td>Recruiting</td>
<td>May 2017</td>
</tr>
<tr>
<td>NCT02043730</td>
<td>Locally advanced, unresectable</td>
<td>nab-Pac + Gem versus Gem alone</td>
<td>II</td>
<td>Ongoing, not recruiting</td>
<td>January 2017</td>
</tr>
<tr>
<td>NCT01844817</td>
<td>Metastatic</td>
<td>nab-Pac + Gem ± OGX-427</td>
<td>II</td>
<td>Recruiting</td>
<td>May 2016</td>
</tr>
<tr>
<td>NCT01839487</td>
<td>Metastatic, previously untreated</td>
<td>nab-Pac + Gem versus PEGPH20 versus nab-Pac + Gem</td>
<td>II</td>
<td>Recruiting</td>
<td>April 2016</td>
</tr>
<tr>
<td>NCT01834235</td>
<td>Metastatic, locally advanced, or unresectable</td>
<td>nab-Pac + Gem ± NPC-1C</td>
<td>I, II</td>
<td>Recruiting</td>
<td>October 2015</td>
</tr>
<tr>
<td>NCT01461915</td>
<td>Metastatic</td>
<td>nab-Pac + Gem ± ODSH</td>
<td>II</td>
<td>Recruiting</td>
<td>March 2013</td>
</tr>
<tr>
<td>NCT02101021</td>
<td>Metastatic, first line</td>
<td>nab-Pac + Gem + momelotinib</td>
<td>II</td>
<td>Recruiting</td>
<td>September 2016</td>
</tr>
</tbody>
</table>

Notes: *Treatment regimen to be chosen based on molecular profiling. LDE-225 is a Hedgehog inhibitor; FG-3019 is an anti-fibrotic antibody; and NPC-1C is a chimeric monoclonal antibody.

Abbreviations: nab-Pac, nab-paclitaxel; Gem, gemcitabine; FOLFIRINOX, 5-fluorouracil, leucovorin, irinotecan, oxaliplatin; ODSH, 2-0, 3-0 desulfated heparin.
Conclusion
In this era of improved outcomes with molecularly targeted antineoplastic therapy, PDA had remained an obstinate exception due to the lack of clearly identified targetable oncogenic pathways. However, through better understanding of tumor biology, it has become possible to devise methods to improve drug delivery to a complex tumor microenvironment in as the case of PDA. The development of nab-paclitaxel and its success in the treatment of metastatic PDA is a prime example of the interface between concepts of nanotechnology and the ingenious principles of drug development to target this recalcitrant disease by exploiting the tumor’s own biological properties, such as its desmoplastic stroma, macropinocytosis, and reliance on albumin for its metabolic needs. The combination of nab-paclitaxel and gemcitabine has emerged as a new paradigm in the management of metastatic PDA.

Disclosure
CDW has received clinical research support and honoraria, Celgene Inc. VN has no conflicts of interest to report.

References
50. Commisso C, Davidson SM, Soydaner-Azeloglu RG, et al. SPARC/osteonectin is a
51. Sato N, Fukushima N, Maehara N, et al. SPARC/osteonecin is a